Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell therapies for the treatment of haematological malignancies, has launched a USD42m Series A financing round led by 5AM Ventures and RA Capital Management, it was reported on Friday.
Johnson & Johnson Innovation – JJDC, Incorporated, Novartis Institutes for BioMedical Research (NIBR) and Osage University Partners also participated in the round, as well as Vor co-founder, PureTech Health. The company plans to use the proceeds from the financing to advance its lead HSC-based candidate for the treatment of acute myeloid leukaemia towards the clinic, and to further build its pipeline to treat hematologic malignancies.
Kush Parmar, MD, PhD, managing partner at 5AM Ventures, who has joined the Vor Biopharma board of directors as executive chair, stated: "Vor's unique and patented technology platform for enabling targeted immunotherapies using engineered HSCs has the potential to disrupt the treatment landscape for hematologic malignancies. We are excited to work with Vor to drive this next chapter of growth forward."
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval